Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of Pyridostigmine to Highly
Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant
patients in which viral load diminishes, but T-cell levels remain low after the initiation of
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran